Ronald Asbury Andrews is CEO at OncoCyte Corp (OCX). They have made 10 open-market trades across 3 companies since 2007, most recently 2026-10-01.
CIK 0001299153
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
10 open-market purchases totalling $43.3M since 2007, never a sale. Across 7 scored buys the stock is down 18.2% at ninety days, and 23.8 points behind the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 57% | 29% | 14% |
| Avg Move | -4.1% | -5.5% | -18.2% |
| Alpha | -8.2% | -10.2% | -23.8% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| OCX | BUY | 2022-08-16 | 2022-08-18 | $0.96 | $38K | -13.2% | -4.8% | -58.5% |
| OCX | BUY | 2022-03-16 | 2022-03-17 | $1.28 | $64K | +9.4% | -12.7% | -26.1% |
| OCX | BUY | 2021-03-19 | 2021-03-22 | $4.79 | $53K | +4.4% | -11.6% | +11.8% |
| OCX | BUY | 2020-08-03 | 2020-08-04 | $1.35 | $54K | -11.2% | -37.6% | -25.4% |
| OCX | BUY | 2020-03-31 | 2020-04-01 | $2372.00 | $42.7M | +6.9% | +16.6% | -12.0% |
| OCX | BUY | 2020-03-30 | 2020-04-01 | $2.30 | $208K | +6.9% | +16.6% | -12.0% |
| LIFE | BUY | 2012-04-27 | 2012-05-01 | $46.49 | $155K | -32.1% | -5.2% | -5.2% |
| CLRT | BUY | 2010-03-12 | 2010-03-15 | $2.41 | $29K | N/A | N/A | N/A |
| CLRT | BUY | 2008-09-18 | 2008-09-19 | $1.93 | $14K | N/A | N/A | N/A |
| CLRT | BUY | 2007-05-07 | 2007-05-08 | $1.92 | $10K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
| CLRT |
| 500,000 |
| — |
| Total | $2.6M |
Shares reported on the most recent Form 4, priced at the 2026-10-01 close. 3 holdings could not be priced and are excluded from the total.